Clinical trials: Central Line
Progressive Supranuclear Palsy
Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy
This study will examine the safety and effectiveness of an experimental drug called GDNF delivered through an investigational device to treat progressive supranuclear palsy (PSP).
- Trial name
- NCT00005903
- Testing
- GDNF & Synchro Med Infusion System
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Bacterial Infections
Safety and Efficacy Study of Angiotech Central Venous Catheter to Prevent Bacterial Catheter Colonization
The main purpose of this study is to determine if the Angiotech central venous catheter (CVC) is equal in effectiveness to a CVC coated with chlorhexidine and silver sulfadiazine in preventing bacterial catheter colonization.
- Trial name
- NCT00288418
- Testing
- Central Venous Catheter
- Where
- 21 sites in United States
- Volunteers
- 960 people
- Sponsor
- Angiotech Pharmaceuticals
Patients With Moderate to Severe Perioral Lines
JUVEDERM® Ultra XC vs. Belotero Balance® for Perioral Lines
A prospective, randomized, controlled, multi-center study of the safety and effectiveness of JUVEDERM® Ultra XC injectable gel versus Belotero Balance® for perioral lines
- Trial name
- NCT01970397
- Testing
- JUVEDERM® Ultra XC, Belotero Balance®
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Allergan
Pancreatic Ductal Adenocarcinoma (PDAC)
A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma
The purpose of this study is to evaluate the efficacy and safety of CEND-1 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo as first-line treatment in patients with Locally Advanced…
- Trial name
- NCT06261359
- Testing
- CEND-1, Gemcitabine, Nab paclitaxel
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Metastatic Breast Cancer
Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer
This randomized, double-blind, placebo controlled phase II trial is studying how well capecitabine works when given in combination with WX-671 or when given alone in treating patients receiving first-line therapy for her2negative…
- Trial name
- NCT00615940
- Testing
- WX-671
- Where
- 20 sites in United States, Belgium and 3 more
- Volunteers
- 132 people
- Sponsor
- Heidelberg Pharma AG
Lung Cancer Non-small Cell Stage IV
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer
This is a phase III , randomized, double-blinded, multicenter clinical study to compare efficacy and safety of AK105 (Anti-PD1 antibody) combined with Carboplatin and Pemetrexed vs Placebo combined with Carboplatin and Pemetrexed…
- Trial name
- NCT03866980
- Testing
- AK105, carboplatin, pemetrexed
- Where
- 2 sites in China
- Volunteers
- 164 people
- Sponsor
- Akeso
High-risk Large B-cell Lymphoma (LBCL)
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.
- Trial name
- ZUMA-23 (NCT05605899)
- Testing
- Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine
- Where
- 85 sites in United States, Australia and 10 more
- Volunteers
- 300 people
- Sponsor
- Kite, A Gilead Company
Pancreatic Cancer
A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
This is a Phase 3, randomized, double-blind clinical trial aimed at evaluating the efficacy and safety of Ivonescimab plus chemotherapy with or without AK117 versus placebo plus chemotherapy in patients with metastatic pancreatic…
- Trial name
- NCT06953999
- Testing
- Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine
- Where
- 3 sites in China
- Volunteers
- 999 people
- Sponsor
- Akeso
Catheter-Related Infections
Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age
This study is a post-marketing approval requirement to assess the safety and time to Catheter-related Bloodstream Infections (CRBSI) of DefenCath in pediatric population (birth to less than 18 years of age) who are on chronic HD…
- Trial name
- NCT06714864
- Testing
- (taurolidine and heparin) catheter lock solution, Standard of Care
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- CorMedix Therapeutics
Carcinoma，Non-Small-Cell Lung
A Prospective Multi-center Phase III Randomized Controlled Trial
The purpose of this study is to investigate the PFS, ORR, OS and overall toxicity value（OTV）on advanced adenocarcinoma treated with nedaplatin or cisplatin combined with pemetrexed.
- Trial name
- NACA (NCT02607592)
- Testing
- cisplatin and pemetrexed, nedaplatin+pemetrexed
- Where
- China
- Volunteers
- 293 people
- Sponsor
- Sun Yat-sen University
Lateral Canthal Lines, Crow's Feet
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
The purpose of this study is to evaluate the safety and efficacy of RT001 to treat moderate to severe lateral canthal lines in adults.
- Conditions
- Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
- Trial name
- NCT00888914
- Testing
- RT001, Vehicle Comparator
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Revance Therapeutics, Inc.
Skin Aging
A Clinical Study to Evaluate the Efficacy and Safety of Monopolar Radiofrequency Combined With SkinCeuticals A.G.E and Skinceuticals CE FERULIC for Improving Facial Skin Elasticity, Tightening and Fading Fine Lines
A Prospective, Single-center, Single-blind, Randomized split-face, controlled trial will be conducted. The goal of this clinical trial is to evaluate the efficacy and safety of monopolar radiofrequency combined with SkinCeuticals…
- Trial name
- NCT06228833
- Testing
- monopolar radiofrequency, SkinCeuticals A.G.E and Skinceuticals CE FERULIC, Standard Cream
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Yes Skin Medical Group
HER2-positive Gastric Cancer
RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer
A single-arm, single-center phase II trial study to assess the efficacy and safety of disitamab vedotin plus cadonilimab as first-line therapy for HER2-overexpressing advanced stomach carcinoma
- Trial name
- NCT06492317
- Testing
- Disitamab Vedotin, Cadonilimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or…
- Trial name
- NILE (NCT03682068)
- Testing
- Durvalumab, Tremelimumab, Cisplatin + Gemcitabine
- Where
- 222 sites in United States, Argentina and 20 more
- Volunteers
- 1,246 people
- Sponsor
- AstraZeneca
Catheterization, Central Venous
Central Line Catheterization With Flexible Tip Straight Guidewire in Small Children
The purpose of this study is to compare the differences in central venous catheter insertion time, success rate, and complication between the flexible tip straight guidewire and J-tip guidewire for ultrasound-guided central…
- Trial name
- NCT03530618
- Testing
- Flexible tip straight guidewire, J-tip
- Where
- South Korea
- Volunteers
- 88 people
- Sponsor
- Seoul National University Hospital
Brain Death, Respiration, Artificial
Miniature In-line Respirator
This first-in-human pilot study will test an investigational miniature breathing device called the Hope inVent. The device is a small, single-use, in-line respirator that connects to a breathing tube and uses compressed oxygen to…
- Trial name
- NCT07768215
- Testing
- Hope inVent
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Home Parenteral Nutrition, Central Venous Catheter
Taurolidine Lock in Long Term Parenteral Nutrition
Taurolidine alone or in combination with citrate have been proposed for locking the catheter to reduce the number of catheter infections.
- Trial name
- NCT02009189
- Testing
- 2% Taurolidine Lock, 1.35% Taurolidine
- Where
- Poland
- Volunteers
- 30 people
- Sponsor
- Stanley Dudrick's Memorial Hospital
Advanced Non-small Cell Lung Cancer, HER2 Mutation
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations.
- Trial name
- SOHO-02 (NCT06452277)
- Testing
- Sevabertinib, Pembrolizumab, Cisplatin
- Where
- 279 sites in United States, Argentina and 34 more
- Volunteers
- 444 people
- Sponsor
- Bayer
Glabellar Frown Lines
Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
This study is intended to evaluate long-term safety and efficacy of MBA-P01 in treatment of glabellar lines.
- Trial name
- NCT05321979
- Testing
- MBA-P01
- Where
- South Korea
- Volunteers
- 253 people
- Sponsor
- Medytox Korea
Triple Negative Breast Neoplasms
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer
- Trial name
- BEGONIA (NCT03742102)
- Testing
- Durvalumab, Capivasertib, Oleclumab
- Where
- 32 sites in United States, Canada and 4 more
- Volunteers
- 243 people
- Sponsor
- AstraZeneca